Almstead Sells Shares of PTC Therapeutics
PTC Therapeutics' CTO Almstead sold 23,749 shares on June 22, 2026.
Key Points
- Almstead Neil Gregory, CTO of PTC Therapeutics, sold 23,749 shares on June 22, 2026.
- Shares of PTC Therapeutics traded near $82.13 on Thursday, with a market cap of about $6.72 billion.
- Analysts have set new price targets for PTCT, with Citigroup assuming coverage with a $108 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Almstead Neil Gregory, the Chief Technical Operations Officer at PTC Therapeutics, Inc. (NasdaqGS: PTCT), sold 23,749 shares on June 22, 2026. The transaction was not planned under Rule 10b5-1. Shares of PTC Therapeutics traded near $82.13 on Thursday.
Insider Buying and Selling at PTC Therapeutics, Inc.
Neil Gregory Almstead, the Chief Technical Operations Officer of PTC Therapeutics, sold 23,749 shares on June 22, 2026, at an average price of $80.90. This transaction was not part of a pre-arranged trading plan. Additionally, Christine Marie Utter, the Senior Vice President and Chief Accounting Officer, sold 19,686 shares on June 17, 2026, while Mark Elliott Boulding, Executive VP and CLO, sold 10,462 shares on June 17, 2026, under a planned trading plan.
Other Institutional Activity in PTC Therapeutics
Several institutional investors have been active in PTC Therapeutics. BlackRock, Inc. increased its holdings by 169,652 shares, ending with 12,948,717 shares valued at about $882.2 million. Janus Henderson Group PLC significantly boosted its position by 2,342,101 shares, now holding 7,193,433 shares worth approximately $490.0 million. Vanguard Portfolio Management LLC opened a new position with 4,804,594 shares valued at $327.3 million. State Street Corp added 140,393 shares to its holdings, bringing its total to 4,346,519 shares valued at $296.1 million.
PTC Therapeutics, Inc. Stock Up 17.2%
Shares of PTC Therapeutics, Inc. (NasdaqGS: PTCT) traded near $82.13 on Thursday. The company has a market cap of approximately $6.72 billion and a forward P/E ratio of 29.1. With a beta of 0.55, the stock has seen a 52-week range between $43.18 and $87.50. Its 50-day moving average is $71.02, and the 200-day moving average is $70.29. The company maintains a current ratio of 2.44 and a quick ratio of 2.29.
$PTCT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 9, 2026, Citigroup assumed coverage of PTC Therapeutics with a "buy" rating and a price target of $108. Jefferies upgraded the stock to a "buy" on May 27, 2026, with a target of $85. TD Cowen also upgraded it to "buy" on May 8, 2026, setting a target of $90. Overall, the consensus among 14 analysts is a "buy" rating with an average target price of $93.93.
About PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company based in Warren, New Jersey. It focuses on discovering, developing, and commercializing medicines for rare disorders affecting children and adults. The company offers treatments like Translarna and Emflaza for Duchenne muscular dystrophy and Evrysdi for spinal muscular atrophy. PTC is also working on a pipeline of therapies for conditions such as phenylketonuria and Huntington's disease. Dr. Matthew B. Klein serves as the CEO, and the company employs about 991 people.
Bottom Line
Insider activity at PTC Therapeutics reflects ongoing transactions by key executives, including recent sales by Almstead Neil Gregory. Investors watch these moves closely for insights into company leadership's confidence. The stock's activity and analyst ratings suggest a positive outlook, but remember that insider transactions may not indicate future performance.
Get PTC Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PTCT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.